Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Bluejay Diagnostics, Inc.

Get SEC filing alerts via email and in your feed for Bluejay Diagnostics, Inc.

BJDX

Bluejay Diagnostics, Inc.

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. develops rapid diagnostic testing solutions for critical care settings using its proprietary Symphony platform, which combines an analyzer and single-use cartridges to measure biomarkers like interleukin-6 (IL-6) from whole blood. Targeting hospitals’ ICUs and ERs, Bluejay aims to provide fast, accurate results to improve patient management, with a business model focused on recurring cartridge sales and expanding test menus for infectious and inflammatory diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Bluejay Diagnostics, Inc.

1
1
Bluejay Diagnostics, Inc. Bluejay Diagnostics Reports Q1 2026 Financial Results with Increased Net Loss

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Bluejay Diagnostics, Inc. Bluejay Diagnostics Reports $6.8 Million Net Loss for Fiscal Year 2025, Faces Funding Challenges

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Bluejay Diagnostics, Inc. Bluejay Diagnostics Reports $1.6 Million Net Loss in Q3 2025, Faces Financial Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Bluejay Diagnostics, Inc. Bluejay Diagnostics Reports Decreased Net Loss and Financial Challenges as of June 30, 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Bluejay Diagnostics, Inc. Bluejay Diagnostics Reports $1.86 Million Net Loss in Q1 2025, Seeks $30 Million in Funding

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Bluejay Diagnostics, Inc. Bluejay Diagnostics Reports $7.7 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Bluejay Diagnostics, Inc. Bluejay Diagnostics Reports Improved Financials, Reduced Losses, and Advancements in Symphony Technology Platform

Via official filing (AI summary) | over 1 year ago | 0 comments